Enrico Franceschi

1: Crinò L, Franceschi E, Scopece L. HER-2 inhibitors: clinical results. Suppl Tumori. 2002 Nov-Dec;1(6):S3-4. PMID: 12658892.

2: Lodi R, Setola E, Tonon C, Ambrosetto P, Franceschi E, Crinò L, Barbiroli B, Cortelli P. Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration. Magn Reson Imaging. 2003 Nov;21(9):1003-7. doi: 10.1016/s0730-725x(03)00214-5. PMID: 14684203.

3: Gori S, Colozza M, Mosconi AM, Franceschi E, Basurto C, Cherubini R, Sidoni A, Rulli A, Bisacci C, De Angelis V, Crinò L, Tonato M. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer. 2004 Jan 12;90(1):36-40. doi: 10.1038/sj.bjc.6601485. PMID: 14710203; PMCID: PMC2395328.

4: Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, Dell'Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJ. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer. 2004 Jul;40(11):1682-8. doi: 10.1016/j.ejca.2004.03.008. PMID: 15251157.

5: Franceschi E, Cavallo G, Scopece L, Paioli A, Pession A, Magrini E, Conforti R, Palmerini E, Bartolini S, Rimondini S, Esposti RD, Crinò L. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br J Cancer. 2004 Sep 13;91(6):1038-44. doi: 10.1038/sj.bjc.6602105. PMID: 15305187; PMCID: PMC2747702.

6: Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer. 2005 Jun 1;103(11):2344-8. doi: 10.1002/cncr.21033. PMID: 15844174.

7: Brandes AA, Cavallo G, Reni M, Tosoni A, Nicolardi L, Scopece L, Franceschi E, Sotti G, Talacchi A, Turazzi S, Ermani M. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer. 2005 Jul 1;104(1):143-8. doi: 10.1002/cncr.21110. PMID: 15912507.

8: Franceschi E, Cavallo G, Scopece L, Esposti RD, Paioli G, Paioli A, Palmerini E, Foschini MP, Marliani AF, Crinò L. Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis. J Neurooncol. 2005 Jul;73(3):261-4. doi: 10.1007/s11060-004-5672-5. PMID: 15980977.

9: Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer. 2005 Dec 1;104(11):2473-6. doi: 10.1002/cncr.21564. PMID: 16270316.

10: Franceschi E, Scopece L, Gori S, Chiari R, Crino L. Primary and metastatic brain tumors. Forum (Genova). 2006;14(1):E2. PMID: 16873085.

11: Tosoni A, Cavallo G, Ermani M, Scopece L, Franceschi E, Ghimenton C, Gardiman M, Pasetto L, Blatt V, Brandes AA. Is protracted low-dose temozolomide feasible in glioma patients? Neurology. 2006 Feb 14;66(3):427-9. doi: 10.1212/01.wnl.0000196465.83423.ec. PMID: 16476947.

12: Brandes AA, Franceschi E. New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology. Expert Rev Anticancer Ther. 2006 Aug;6(8):1129-31. doi: 10.1586/14737140.6.8.1129. PMID: 16925479.

13: Scopece L, Franceschi E, Cavallo G, Paioli A, Paioli G, Conforti R, Palmerini E, Berzioli C, Spagnolli F, Esposti RD, Crinò L. Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors. J Neurooncol. 2006 Sep;79(3):299-305. doi: 10.1007/s11060-006-9144-y. Epub 2006 Apr 28. PMID: 16645720.

14: Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M; GICNO. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol. 2006 Oct 10;24(29):4746-53. doi: 10.1200/JCO.2006.06.3891. Epub 2006 Sep 5. PMID: 16954518.

15: Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crinò L, Ermani M; GICNO. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer. 2006 Nov 6;95(9):1155-60. doi: 10.1038/sj.bjc.6603376. Epub 2006 Oct 3. PMID: 17024124; PMCID: PMC2360560.

16: Battaglia S, Marliani AF, Stafa A, Franceschi E, Agati R. Extracentral nervous system metastases from medulloblastoma. A case report. Neuroradiol J. 2007 Jan 31;19(6):799-803. doi: 10.1177/197140090601900618. Epub 2007 Jan 14. PMID: 24351310.

17: Compostella A, Tosoni A, Blatt V, Franceschi E, Brandes AA. Prognostic factors for anaplastic astrocytomas. J Neurooncol. 2007 Feb;81(3):295-303. doi: 10.1007/s11060-006-9232-z. Epub 2006 Sep 26. PMID: 17001519.

18: Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, Ilariucci F, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri AJ. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007 Mar 26;96(6):864-7. doi: 10.1038/sj.bjc.6603660. Epub 2007 Feb 27. PMID: 17325700; PMCID: PMC2360092.

19: Franceschi E, Tosoni A, Paioli A, Cavallo G, Spagnolli F, Brandes AA. Challenges and progress in the treatment of adult medulloblastomas. Future Oncol. 2007 Apr;3(2):115-7. doi: 10.2217/14796694.3.2.115. PMID: 17381408.

20: Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, Scopece L, Blatt V, Urbini B, Pession A, Tallini G, Crinò L, Brandes AA. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2007 Apr 10;96(7):1047-51. doi: 10.1038/sj.bjc.6603669. Epub 2007 Mar 13. PMID: 17353924; PMCID: PMC2360116.

21: Brandes AA, Tosoni A, Franceschi E. Adjuvant therapy in glioblastomas: false steps and real advances. Expert Rev Anticancer Ther. 2007 May;7(5):607-8. doi: 10.1586/14737140.7.5.607. PMID: 17492923.

22: Tosoni A, Franceschi E, Esposti RD, Brandes AA. Trastuzumab in CNS progressive metastatic breast cancer. Future Oncol. 2007 Aug;3(4):367-9. doi: 10.2217/14796694.3.4.367. PMID: 17661709.

23: Brandes AA, Franceschi E, Tosoni A, Blatt V, Ermani M. Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer. 2007 Nov 1;110(9):2035-41. doi: 10.1002/cncr.23003. PMID: 17823910.

24: Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res. 2008 Feb 15;14(4):957-60. doi: 10.1158/1078-0432.CCR-07-1810. PMID: 18281526.

25: Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163. PMID: 18445844.

26: Franceschi E, Tosoni A, Brandes AA. Adjuvant temozolomide: how long and how much? Expert Rev Anticancer Ther. 2008 May;8(5):663-5. doi: 10.1586/14737140.8.5.663. PMID: 18471038.

27: Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, Franceschi E. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol. 2008 Jun;10(3):361-7. doi: 10.1215/15228517-2008-008. Epub 2008 Apr 9. PMID: 18401015; PMCID: PMC2563059.

28: Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G, Vecht C. Glioblastoma in adults. Crit Rev Oncol Hematol. 2008 Aug;67(2):139-52. doi: 10.1016/j.critrevonc.2008.02.005. Epub 2008 Apr 3. PMID: 18394916.

29: Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, Brandes AA. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol. 2008 Sep;89(2):179-85. doi: 10.1007/s11060-008-9600-y. Epub 2008 Apr 23. PMID: 18431544.

30: Franceschi E, Tosoni A, Pozzati E, Brandes AA. Association between response to primary treatments and MGMT status in glioblastoma. Expert Rev Anticancer Ther. 2008 Nov;8(11):1781-6. doi: 10.1586/14737140.8.11.1781. PMID: 18983238.

31: Tosoni A, Franceschi E, Brandes AA. Chemotherapy in breast cancer patients with brain metastases: have new chemotherapic agents changed the clinical outcome? Crit Rev Oncol Hematol. 2008 Dec;68(3):212-21. doi: 10.1016/j.critrevonc.2008.04.004. Epub 2008 Jun 12. PMID: 18550383.

32: Marucci G, Morandi L, Magrini E, Farnedi A, Franceschi E, Miglio R, Calò D, Pession A, Foschini MP, Eusebi V. Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch. 2008 Dec;453(6):599-609. doi: 10.1007/s00428-008-0685-7. Epub 2008 Oct 25. PMID: 18953566.

33: Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amistà P, Morandi L, Spagnolli F, Ermani M. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol. 2009 Mar 10;27(8):1275-9. doi: 10.1200/JCO.2008.19.4969. Epub 2009 Feb 2. PMID: 19188675.

34: Franceschi E, Tosoni A, Bartolini S, Mazzocchi V, Fioravanti A, Brandes AA. Treatment options for recurrent glioblastoma: pitfalls and future trends. Expert Rev Anticancer Ther. 2009 May;9(5):613-9. doi: 10.1586/era.09.23. PMID: 19445578.

35: Brandes AA, Franceschi E, Tosoni A, Reni M, Gatta G, Vecht C, Kortmann RD. Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol. 2009 Aug;71(2):165-79. doi: 10.1016/j.critrevonc.2009.02.002. Epub 2009 Mar 19. PMID: 19303318.

36: Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer. 2009 Aug 1;115(15):3512-8. doi: 10.1002/cncr.24406. PMID: 19514084.

37: Brandes AA, Tosoni A, Franceschi E, Blatt V, Santoro A, Faedi M, Amistà P, Gardiman M, Labianca R, Bianchini C, Ermani M, Reni M. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2009 Sep;64(4):769-75. doi: 10.1007/s00280-009-0926-8. Epub 2009 Jan 24. PMID: 19169684; PMCID: PMC2717374.

38: Franceschi E, Tosoni A, Girardi F, Brandes AA. Bevacizumab in brain tumors: ready for primetime? Future Oncol. 2009 Oct;5(8):1183-4. doi: 10.2217/fon.09.98. PMID: 19852729.

39: Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist. 2010;15(7):683-94. doi: 10.1634/theoncologist.2009-0235. Epub 2010 Jun 14. PMID: 20547589; PMCID: PMC3228010.

40: Brandes AA, Franceschi E, Tosoni A, Degli Esposti R. Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. Expert Rev Anticancer Ther. 2010 Feb;10(2):179-84. doi: 10.1586/era.09.156. PMID: 20131994.

41: Morandi L, Franceschi E, de Biase D, Marucci G, Tosoni A, Ermani M, Pession A, Tallini G, Brandes A. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. BMC Cancer. 2010 Feb 18;10:48. doi: 10.1186/1471-2407-10-48. PMID: 20167086; PMCID: PMC2843669.

42: Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, Calbucci F, Ermani M. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol. 2010 Mar;12(3):283-8. doi: 10.1093/neuonc/nop050. Epub 2010 Feb 1. PMID: 20167816; PMCID: PMC2940594.

43: Brandes AA, Franceschi E. Neuro-oncology: Genetic variation in pediatric and adult brain tumors. Nat Rev Neurol. 2010 Dec;6(12):653-4. doi: 10.1038/nrneurol.2010.176. PMID: 21131914.

44: Brandes AA, Franceschi E. New agents and new end points for recurrent gliomas. J Clin Oncol. 2011 Mar 20;29(9):e245-6; author reply e247. doi: 10.1200/JCO.2010.33.2809. Epub 2011 Jan 31. PMID: 21282544.

45: Franceschi E, Brandes AA. Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe? Expert Rev Anticancer Ther. 2011 May;11(5):657-60. doi: 10.1586/era.11.44. PMID: 21554036.

46: Brandes AA, Franceschi E. Primary brain tumors in the elderly population. Curr Treat Options Neurol. 2011 Aug;13(4):427-35. doi: 10.1007/s11940-011-0126-9. PMID: 21484262.

47: Franceschi E, Agati R, Brandes AA. End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. Expert Rev Anticancer Ther. 2011 Nov;11(11):1713-7. doi: 10.1586/era.11.164. PMID: 22050020.

48: Fellay CN, Frappaz D, Sunyach MP, Franceschi E, Brandes AA, Stupp R. Medulloblastomas in adults: prognostic factors and lessons from paediatrics. Curr Opin Neurol. 2011 Dec;24(6):626-32. doi: 10.1097/WCO.0b013e32834cd4b1. PMID: 22027544.

49: de Biase D, Visani M, Morandi L, Marucci G, Taccioli C, Cerasoli S, Baruzzi A, Pession A; PERNO Study Group. miRNAs expression analysis in paired fresh/frozen and dissected formalin fixed and paraffin embedded glioblastoma using real-time pCR. PLoS One. 2012;7(4):e35596. doi: 10.1371/journal.pone.0035596. Epub 2012 Apr 18. PMID: 22530056; PMCID: PMC3329457.

50: Brandes AA, Franceschi E, Gorlia T, Wick W, Jacobs AH, Baumert BG, van den Bent M, Weller M, Stupp R; European Organisation for Research and Treatment of Cancer Brain Tumour Group. Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. Eur J Cancer. 2012 Apr;48(6):896-903. doi: 10.1016/j.ejca.2011.10.027. Epub 2011 Nov 24. PMID: 22119352.

51: Franceschi E, Brandes AA. Brain metastases from non-small-cell lung cancer: is there room for improvement? Expert Rev Anticancer Ther. 2012 Apr;12(4):421-3. doi: 10.1586/era.12.20. PMID: 22500678.

52: Bartolotti M, Franceschi E, Di Battista M, Esposti RD, Castaldini L, Baccarini P, Brandes AA. Cytologically confirmed splenic metastases in breast cancer. Future Oncol. 2012 Nov;8(11):1495-500. doi: 10.2217/fon.12.103. PMID: 23148622.

53: Bartolotti M, Franceschi E, Brandes AA. EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. Expert Rev Anticancer Ther. 2012 Nov;12(11):1429-35. doi: 10.1586/era.12.121. PMID: 23249107.

54: Franceschi E, Stupp R, van den Bent MJ, van Herpen C, Laigle Donadey F, Gorlia T, Hegi M, Lhermitte B, Strauss LC, Allgeier A, Lacombe D, Brandes AA. EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro Oncol. 2012 Dec;14(12):1503-10. doi: 10.1093/neuonc/nos256. Epub 2012 Oct 22. PMID: 23090987; PMCID: PMC3499012.

55: Visani M, de Biase D, Marucci G, Taccioli C, Baruzzi A, Pession A; PERNO Study Group. Definition of miRNAs expression profile in glioblastoma samples: the relevance of non-neoplastic brain reference. PLoS One. 2013;8(1):e55314. doi: 10.1371/journal.pone.0055314. Epub 2013 Jan 29. PMID: 23383149; PMCID: PMC3558478.

56: Brandes AA, Bartolotti M, Franceschi E. Second surgery for recurrent glioblastoma: advantages and pitfalls. Expert Rev Anticancer Ther. 2013 May;13(5):583-7. doi: 10.1586/era.13.32. PMID: 23617349.

57: Michelucci R, Pasini E, Meletti S, Fallica E, Rizzi R, Florindo I, Chiari A, Monetti C, Cremonini AM, Forlivesi S, Albani F, Baruzzi A; PERNO Study Group. Epilepsy in primary cerebral tumors: the characteristics of epilepsy at the onset (results from the PERNO study--Project of Emilia Romagna Region on Neuro- Oncology). Epilepsia. 2013 Oct;54 Suppl 7:86-91. doi: 10.1111/epi.12314. PMID: 24099060.

58: Reni M, Cereda S, Milella M, Novarino A, Passardi A, Mambrini A, Di Lucca G, Aprile G, Belli C, Danova M, Bergamo F, Franceschi E, Fugazza C, Ceraulo D, Villa E. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Eur J Cancer. 2013 Nov;49(17):3609-15. doi: 10.1016/j.ejca.2013.06.041. Epub 2013 Jul 27. PMID: 23899530.

59: Brandes AA, Franceschi E. Metastatic process: the seed and the soil from bench to bedside. Future Oncol. 2013 Nov;9(11):1597-8. doi: 10.2217/fon.13.192. PMID: 24156320.

60: Bartolotti M, Franceschi E, Brandes AA. Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. Future Oncol. 2013 Nov;9(11):1653-64. doi: 10.2217/fon.13.90. PMID: 24156325.

61: Franceschi E, Bartolotti M, Poggi R, Di Battista M, Palleschi D, Brandes AA. The role of systemic and targeted therapies in brain metastases. Expert Rev Anticancer Ther. 2014 Jan;14(1):93-103. doi: 10.1586/14737140.2014.856760. Epub 2013 Nov 26. PMID: 24308678.

62: Brandes AA, Franceschi E. Shedding light on adult medulloblastoma: current management and opportunities for advances. Am Soc Clin Oncol Educ Book. 2014:e82-7. doi: 10.14694/EdBook_AM.2014.34.e82. PMID: 24857151.

63: Visani M, de Biase D, Marucci G, Cerasoli S, Nigrisoli E, Bacchi Reggiani ML, Albani F, Baruzzi A, Pession A; PERNO study group. Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III. Mol Oncol. 2014 Mar;8(2):417-30. doi: 10.1016/j.molonc.2013.12.010. Epub 2013 Dec 24. Erratum in: Mol Oncol. 2015 Jan;9(1):334. Erratum in: Mol Oncol. 2015 Jan;9(1):334. PMID: 24412053; PMCID: PMC5528554.

64: Brandes AA, Franceschi E. The metastatic process: a kaleidoscope of concepts. Future Oncol. 2014 Apr;10(5):697-8. doi: 10.2217/fon.14.32. PMID: 24799049.

65: Bartolotti M, Franceschi E, Poggi R, Tosoni A, Di Battista M, Brandes AA. Resistance to antiangiogenic therapies. Future Oncol. 2014 Jun;10(8):1417-25.doi: 10.2217/fon.14.57. PMID: 25052752.

66: Brandes AA, Franceschi E, Ermani M, Tosoni A, Albani F, Depenni R, Faedi M, Pisanello A, Crisi G, Urbini B, Dazzi C, Cavanna L, Mucciarini C, Pasini G, Bartolini S, Marucci G, Morandi L, Zunarelli E, Cerasoli S, Gardini G, Lanza G, Silini EM, Cavuto S, Baruzzi A, Baruzzi A, Albani F, Calbucci F, D'Alessandro R, Michelucci R, Brandes A, Eusebi V, Ceruti S, Fainardi E, Tamarozzi R, Emiliani E, Cavallo M, Franceschi E, Tosoni A, Cavallo M, Fiorica F, Valentini A, Depenni R, Mucciarini C, Crisi G, Sasso E, Biasini C, Cavanna L, Guidetti D, Marcello N, Pisanello A, Cremonini AM, Guiducci G, de Pasqua S, Testoni S, Agati R, Ambrosetto G, Bacci A, Baldin E, Baldrati A, Barbieri E, Bartolini S, Bellavista E, Bisulli F, Bonora E, Bunkheila F, Carelli V, Crisci M, Dall'Occa P, de Biase D, Ferro S, Franceschi C, Frezza G, Grasso V, Leonardi M, Marucci G, Mazzocchi V, Morandi L, Mostacci B, Palandri G, Pasini E, Pastore Trossello M, Pession A, Ragazzi M, Riguzzi P, Rinaldi R, Rizzi S, Romeo G, Spagnolli F, Tinuper P, Trocino C, Cerasoli S, Dall'Agata M, Faedi M, Frattarelli M, Gentili G, Giovannini A, Iorio P, Pasquini U, Galletti G, Guidi C, Neri W, Patuelli A, Strumia S, Casmiro M, Gamboni A, Rasi F, Cruciani G, Cenni P, Dazzi C, Guidi A, Zumaglini F, Amadori A, Pasini G, Pasquinelli M, Pasquini E, Polselli A, Ravasio A, Viti B, Sintini M, Ariatti A, Bertolini F, Bigliardi G, Carpeggiani P, Cavalleri F, Meletti S, Nichelli P, Pettorelli E, Pinna G, Zunarelli E, Artioli F, Bernardini I, Costa M, Greco G, Guerzoni R, Stucchi C, Iaccarino C, Rizzi R, Zuccoli G, Api P, Cartei F, Fallica E, Granieri E, Latini F, Lelli G, Monetti C, Ramponi V, Saletti A, Schivalocchi R, Seraceni S, Tola MR, Urbini B, Giorgi C, Montanari E, Cerasti D, Crafa P, Dascola I, Florindo I, Mazza S, Servadei F, Silini E, Torelli P, Immovilli P, Morelli N, Vanzo C. Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center? Neurooncol Pract. 2014 Dec;1(4):166-171. doi: 10.1093/nop/npu021. Epub 2014 Aug 28. PMID: 26034628; PMCID: PMC4369716.

67: Franceschi E, Ermani M, Bartolini S, Bartolotti M, Poggi R, Tallini G, Marucci G, Fioravanti A, Tosoni A, Agati R, Bacci A, Pozzati E, Morandi L, Balestrini D, Ghimenton C, Crisi G, Brandes AA. Post progression survival in glioblastoma: where are we? J Neurooncol. 2015 Jan;121(2):399-404. doi: 10.1007/s11060-014-1651-7. Epub 2014 Nov 1. PMID: 25366365.

68: Franceschi E, Brandes AA. The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials. CNS Oncol. 2015;4(3):117-9. doi: 10.2217/cns.15.7. Epub 2015 Apr 23. PMID: 25906382; PMCID: PMC6088337.

69: Franceschi E. Second-Line Chemotherapy in Recurrent Glioblastoma—Still Controversial. Oncol Res Treat. 2015;38(7-8):345-6. doi: 10.1159/000435903. Epub2015 Jul 1. PMID: 26278577.

70: Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist. 2015 Feb;20(2):166-75. doi: 10.1634/theoncologist.2014-0330. Epub 2015 Jan 7. PMID: 25568148; PMCID: PMC4319633.

71: Franceschi E, Bartolotti M, Tosoni A, Bartolini S, Sturiale C, Fioravanti A, Pozzati E, Galzio R, Talacchi A, Volpin L, Morandi L, Danieli D, Ermani M, Brandes AA. The effect of re-operation on survival in patients with recurrent glioblastoma. Anticancer Res. 2015 Mar;35(3):1743-8. PMID: 25750337.

72: Marucci G, Fabbri PV, Morandi L, De Biase D, Di Oto E, Tallini G, Sturiale C, Franceschi E, Frezza GP, Foschini MP. Pathological spectrum in recurrences of glioblastoma multiforme. Pathologica. 2015 Mar;107(1):1-8. PMID: 26591624.

73: Yeung TP, Wang Y, He W, Urbini B, Gafà R, Ulazzi L, Yartsev S, Bauman G, Lee TY, Fainardi E; Project of Emilia-Romagna Region on Neuro-Oncology Study Group. Survival prediction in high-grade gliomas using CT perfusion imaging. J Neurooncol. 2015 May;123(1):93-102. doi: 10.1007/s11060-015-1766-5. Epub 2015 Apr 11. Erratum in: J Neurooncol. 2015 Oct;125(1):223-4. PMID: 25862005.

74: Brandes AA, Bartolotti M, Marucci G, Ghimenton C, Agati R, Fioravanti A, Mascarin M, Volpin L, Ammannati F, Masotto B, Gardiman MP, De Biase D, Tallini G, Crisi G, Bartolini S, Franceschi E. New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. Crit Rev Oncol Hematol. 2015 Jun;94(3):348-59. doi: 10.1016/j.critrevonc.2014.12.016. Epub 2014 Dec 31. PMID: 25600839.

75: Franceschi E, Bartolotti M, Brandes AA. Bevacizumab in recurrent glioblastoma: open issues. Future Oncol. 2015 Oct;11(19):2655-2665. doi: 10.2217/fon.15.125. Epub 2015 Sep 11. PMID: 26357999.

76: Visani M, Acquaviva G, Fiorino S, Bacchi Reggiani ML, Masetti M, Franceschi E, Fornelli A, Jovine E, Fabbri C, Brandes AA, Tallini G, Pession A, de Biase D. Contribution of microRNA analysis to characterisation of pancreatic lesions: a review. J Clin Pathol. 2015 Nov;68(11):859-69. doi: 10.1136/jclinpath-2015-203246. Epub 2015 Aug 27. PMID: 26314585.

77: Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov;16(15):e534-e542. doi: 10.1016/S1470-2045(15)00088-1. PMID: 26545842; PMCID: PMC4638131.

78: Pagliaro G, Pandolfi P, Collina N, Frezza G, Brandes A, Galli M, Avventuroso FM, De Lisio S, Musti MA, Franceschi E, Esposti RD, Lombardo L, Cavallo G, Di Battista M, Rimondini S, Poggi R, Susini C, Renzi R, Marconi L. A Randomized Controlled Trial of Tong Len Meditation Practice in Cancer Patients: Evaluation of a Distant Psychological Healing Effect. Explore (NY). 2016 Jan-Feb;12(1):42-9. doi: 10.1016/j.explore.2015.10.001. Epub 2015 Oct 26. PMID: 26657031.

79: Mazza E, Brandes A, Zanon S, Eoli M, Lombardi G, Faedi M, Franceschi E, Reni M. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2016 Jan;77(1):115-20. doi: 10.1007/s00280-015-2927-0. Epub 2015 Dec 11. PMID: 26659583.

80: Brandes AA, Bartolotti M, Tosoni A, Poggi R, Bartolini S, Paccapelo A, Bacci A, Ghimenton C, Pession A, Bortolotti C, Zucchelli M, Galzio R, Talacchi A, Volpin L, Marucci G, de Biase D, Pizzolitto S, Danieli D, Ermani M, Franceschi E. Patient outcomes following second surgery for recurrent glioblastoma. Future Oncol. 2016;12(8):1039-44. doi: 10.2217/fon.16.9. Epub 2016 Feb 16. PMID: 26880307.

81: Brandes AA, Bartolotti M, Tosoni A, Franceschi E. Nitrosoureas in the Management of Malignant Gliomas. Curr Neurol Neurosci Rep. 2016 Feb;16(2):13. doi: 10.1007/s11910-015-0611-8. PMID: 26750128.

82: Franceschi E, Depenni R, Paccapelo A, Ermani M, Faedi M, Sturiale C, Michiara M, Servadei F, Pavesi G, Urbini B, Pisanello A, Crisi G, Cavallo MA, Dazzi C, Biasini C, Bertolini F, Mucciarini C, Pasini G, Baruzzi A, Brandes AA; PERNO Study Group. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. J Neurooncol. 2016 May;128(1):157-162. doi: 10.1007/s11060-016-2093-1. Epub 2016Mar 4. Erratum in: J Neurooncol. 2018 Jan;136(1):221-222. PMID: 26943851.

83: Franceschi E, Bartolotti M, Paccapelo A, Marucci G, Agati R, Volpin L, Danieli D, Ghimenton C, Gardiman MP, Sturiale C, Poggi R, Mascarin M, Balestrini D, Masotto B, Brandes AA. Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients? J Neurooncol. 2016 Jun;128(2):235-40. doi: 10.1007/s11060-016-2097-x. Epub 2016 Mar 3. PMID: 26940908.

84: Schiffgens S, Wilkens L, Brandes AA, Meier T, Franceschi E, Ermani M, Hartmann C, Sandalcioglu IE, Dumitru CA. Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma. Oncotarget. 2016 Aug 23;7(34):55169-55180. doi: 10.18632/oncotarget.10465. PMID: 27409829; PMCID: PMC5342409.

85: Brandes AA, Finocchiaro G, Zagonel V, Reni M, Caserta C, Fabi A, Clavarezza M, Maiello E, Eoli M, Lombardi G, Monteforte M, Proietti E, Agati R, Eusebi V, Franceschi E. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro Oncol. 2016 Sep;18(9):1304-12. doi: 10.1093/neuonc/now035. Epub 2016 Mar 6.PMID: 26951379; PMCID: PMC4998997.

86: Tosoni A, Franceschi E, Poggi R, Brandes AA. Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences. Curr Treat Options Oncol. 2016 Sep;17(9):49. doi: 10.1007/s11864-016-0422-4. PMID: 27461038.

87: Baldin E, Testoni S, de Pasqua S, Ferro S, Albani F, Baruzzi A, D'Alessandro R; PERNO study group. Incidence of neuroepithelial primary brain tumors among adult population of Emilia-Romagna Region, Italy. Neurol Sci. 2017 Feb;38(2):255-262. doi: 10.1007/s10072-016-2747-y. Epub 2016 Nov 2. Erratum in: Neurol Sci. 2017 Feb;38(2):263. PMID: 27807698.

88: Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977. PMID: 28296618.

89: Brandes AA, Franceschi E, Paccapelo A, Tallini G, De Biase D, Ghimenton C, Danieli D, Zunarelli E, Lanza G, Silini EM, Sturiale C, Volpin L, Servadei F, Talacchi A, Fioravanti A, Pia Foschini M, Bartolini S, Pession A, Ermani M. Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. Oncologist. 2017 Apr;22(4):432-437. doi: 10.1634/theoncologist.2016-0254. Epub 2017 Mar 8. PMID: 28275120; PMCID: PMC5388380.

90: Franceschi E, Minichillo S, Brandes AA. Pharmacotherapy of Glioblastoma: stablished Treatments and Emerging Concepts. CNS Drugs. 2017 Aug;31(8):675-684. doi: 10.1007/s40263-017-0454-8. PMID: 28681349.

91: Brandes AA, Finocchiaro G, Zagonel V, Reni M, Fabi A, Caserta C, Tosoni A, Eoli M, Lombardi G, Clavarezza M, Paccapelo A, Bartolini S, Cirillo L, Agati R, Franceschi E. Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. Oncotarget. 2017 Feb 25;8(33):55575-55581. doi: 10.18632/oncotarget.15735. PMID: 28903444; PMCID: PMC5589683.

92: Visani M, Acquaviva G, Marucci G, Paccapelo A, Mura A, Franceschi E, Grifoni D, Pession A, Tallini G, Brandes AA, de Biase D. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria. J Neurooncol. 2017 Nov;135(2):245-254. doi: 10.1007/s11060-017-2571-0. Epub 2017 Jul 26. PMID: 28748342.

93: Tosoni A, Franceschi E, Pasquini E, Lanese A, Donini E, Foschini MP, Dall'Olio D, Brandes AA. Immunotherapy in head and neck cancer: evidence and perspectives. Immunotherapy. 2017 Dec;9(16):1351-1358. doi: 10.2217/imt-2017-0125. PMID: 29185392.

94: Acquaviva G, Visani M, de Biase D, Marucci G, Franceschi E, Tosoni A, Brandes AA, Rhoden KJ, Pession A, Tallini G. Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1^105GGT) in brain tumors of a cohort of Italian patients. Sci Rep. 2018 Mar 13;8(1):4459. doi: 10.1038/s41598-018-22222-y. PMID: 29535392; PMCID: PMC5849696.

95: Franceschi E, Tosoni A, Minichillo S, Depenni R, Paccapelo A, Bartolini S, Michiara M, Pavesi G, Urbini B, Crisi G, Cavallo MA, Tosatto L, Dazzi C, Biasini C, Pasini G, Balestrini D, Zanelli F, Ramponi V, Fioravanti A, Giombelli E, De Biase D, Baruzzi A, Brandes AA; PERNO Study Group. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power. World Neurosurg. 2018 Apr;112:e342-e347. doi: 10.1016/j.wneu.2018.01.045. Epub 2018 Jan 11. PMID: 29337169.

96: Franceschi E, Lamberti G, Visani M, Paccapelo A, Mura A, Tallini G, Pession A, De Biase D, Minichillo S, Tosoni A, Di Battista M, Cubeddu A, Bartolini S, Brandes AA. Temozolomide rechallenge in recurrent glioblastoma: when is it useful? Future Oncol. 2018 May;14(11):1063-1069. doi: 10.2217/fon-2017-0681. Epub 2018 May 9. PMID: 29741106.

97: Franceschi E, Mura A, De Biase D, Tallini G, Pession A, Foschini MP, Danieli D, Pizzolitto S, Zunarelli E, Lanza G, Bartolini D, Silini EM, Visani M, Di Oto E, Tosoni A, Minichillo S, Lamberti G, Lanese A, Paccapelo A, Bartolini S, Brandes AA. The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival? Future Oncol. 2018 Jul;14(16):1559-1567. doi: 10.2217/fon-2017-0634. Epub 2018 Jun 25. PMID: 29938525.

98: Franceschi E, Lamberti G, Paccapelo A, Di Battista M, Genestreti G, Minichillo S, Mura A, Bartolini S, Agati R, Brandes AA. Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab? J Neurooncol. 2018 Sep;139(2):383-388. doi: 10.1007/s11060-018-2873-x. Epub 2018 Apr 18. PMID: 29671196.

99: Lanese A, Franceschi E, Brandes AA. The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria. Oncol Ther. 2018 Dec;6(2):105-108. doi: 10.1007/s40487-018-0063-9. Epub 2018 Jul 16. PMID: 32700027; PMCID: PMC7359968.

100: Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, hiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. Oncologist. 2019 Apr;24(4):521-528. doi: 10.1634/theoncologist.2018-0290. Epub 2018 Sep 28. PMID: 30266892; PMCID: PMC6459244.

101: Franceschi E, Tosoni A, De Biase D, Lamberti G, Danieli D, Pizzolitto S, unarelli E, Visani M, Di Oto E, Mura A, Minichillo S, Scafati C, Asioli S, Paccapelo A, Bartolini S, Brandes AA. Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option? Oncologist. 2019 May;24(5):664-670. doi: 10.1634/theoncologist.2018-0549. Epub 2019 Feb 18. PMID: 30777895; PMCID: PMC6516106.

102: Franceschi E, Mura A, Lamberti G, De Biase D, Tosoni A, Di Battista M, Argento C, Visani M, Paccapelo A, Bartolini S, Brandes AA. Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas. Future Oncol. 2019 Aug;15(22):2595-2601. doi: 10.2217/fon-2019-0093. Epub 2019 Jul 24. PMID: 31339049.

103: French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Weller M, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, van den Bent M. Defining EGFR amplification status for clinical trial inclusion. Neuro Oncol. 2019 Oct 9;21(10):1263-1272. doi: 10.1093/neuonc/noz096. PMID: 31125418; PMCID: PMC6784284.

104: Mascarin M, Coassin E, Franceschi E, Gandola L, Carrabba G, Brandes AA, Massimino M. Medulloblastoma and central nervous system germ cell tumors in adults: is pediatric experience applicable? Childs Nerv Syst. 2019 Dec;35(12):2279-2287. doi: 10.1007/s00381-019-04340-8. Epub 2019 Aug 14. PMID: 31414168.

105: Franceschi E, Hofer S, Brandes AA, Frappaz D, Kortmann RD, Bromberg J, angouloff-Ros V, Boddaert N, Hattingen E, Wiestler B, Clifford SC, Figarella-Branger D, Giangaspero F, Haberler C, Pietsch T, Pajtler KW, Pfister SM, Guzman R, Stummer W, Combs SE, Seidel C, Beier D, McCabe MG, Grotzer M, Laigle-Donadey F, Stücklin ASG, Idbaih A, Preusser M, van den Bent M, Weller M, Hau P. EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Lancet Oncol. 2019 Dec;20(12):e715-e728. doi: 10.1016/S1470-2045(19)30669-2. PMID: 31797797.

106: Hoogstrate Y, Vallentgoed W, Kros JM, de Heer I, de Wit M, Eoli M, Sepulveda JM, Walenkamp AME, Frenel JS, Franceschi E, Clement PM, Weller M, van Royen ME, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, Golfinopoulos V, van den Bent M, French PJ. EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. Neurooncol Adv. 2019 Dec 9;2(1):vdz051. doi: 10.1093/noajnl/vdz051. PMID: 32642719; PMCID: PMC7212878.

107: Visani M, Marucci G, Biase D, Giangaspero F, Buttarelli FR, Brandes AA, Franceschi E, Acquaviva G, Ciarrocchi A, Rhoden KJ, Tallini G, Pession A. miR-196B-5P and miR-200B-3P Are Differentially Expressed in Medulloblastomas of Adults and Children. Diagnostics (Basel). 2020 Apr 29;10(5):265. doi:

10.3390/diagnostics10050265. Erratum in: Diagnostics (Basel). 2021 Sep 07;11(9): PMID: 32365560; PMCID: PMC7277606.

108: Di Nunno V, Franceschi E, Gatto L, Bartolini S, Brandes AA. Predictive markers of immune response in glioblastoma: hopes and facts. Future Oncol. 2020 May;16(15):1053-1063. doi: 10.2217/fon-2020-0047. Epub 2020 Apr 9. PMID: 32270715.

109: Nunno VD, Franceschi E, Brandes AA. Immunotherapy in elderly patients: should we stay or should we go? Future Oncol. 2020 May;16(15):973-974. doi: 10.2217/fon-2020-0146. Epub 2020 Apr 14. PMID: 32285699.

110: Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, De Vos F, Whenham N, Sanghera P, Weller M, Dubbink HJ, French P, Looman J, Dey J, Krause S, Ansell P, Nuyens S, Spruyt M, Brilhante J, Coens C, Gorlia T, Golfinopoulos V. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2020 May 15;22(5):684-693. doi: 10.1093/neuonc/noz222. Erratum in: Neuro Oncol. 2021 Aug 2;23(8):1415. PMID: 31747009; PMCID: PMC7229258.

111: Erker C, Tamrazi B, Poussaint TY, Mueller S, Mata-Mbemba D, Franceschi E, Brandes AA, Rao A, Haworth KB, Wen PY, Goldman S, Vezina G, MacDonald TJ, Dunkel IJ, Morgan PS, Jaspan T, Prados MD, Warren KE. Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020 Jun;21(6):e317-e329. doi: 10.1016/S1470-2045(20)30173-X. Erratum in: Lancet Oncol. 2020 Aug;21(8):e372. PMID: 32502458.

112: Franceschi E, Frappaz D, Rudà R, Hau P, Preusser M, Houillier C, Lombardi G, Asioli S, Dehais C, Bielle F, Di Nunno V, van den Bent M, Brandes AA, Idbaih A; EURACAN Domain 10. Rare Primary Central Nervous System Tumors in Adults: An Overview. Front Oncol. 2020 Jun 26;10:996. doi: 10.3389/fonc.2020.00996. PMID: 32676456; PMCID: PMC7333775.

113: Brandes AA, Ardizzoni A, Artioli F, Cappuzzo F, Cavanna L, Frassineti GL, Frassoldati A, Leonardi F, Longo G, Maestri A, Tassinari D, Franceschi E, Nunno VD, Pinto C. Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. Future Oncol. 2020 Jul;16(20):1433-1439. doi: 10.2217/fon-2020-0358. Epub 2020 May 21. PMID: 32437242; PMCID: PMC7249540.

114: Franceschi E, Minichillo S, Mura A, Tosoni A, Mascarin M, Tomasello C, Bartolini S, Brandes AA. Adjuvant chemotherapy in average-risk adult edulloblastoma patients improves survival: a long term study. BMC Cancer. 2020 Aug 12;20(1):755. doi: 10.1186/s12885-020-07237-x. PMID: 32787805; PMCID: PMC7425050.

115: Franceschi E, Tosoni A, Bartolini S, Minichillo S, Mura A, Asioli S, Bartolini D, Gardiman M, Gessi M, Ghimenton C, Giangaspero F, Lanza G, Marucci G, Novello M, Silini EM, Zunarelli E, Paccapelo A, Brandes AA. Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. Eur J Cancer. 2020 Sep;137:10-17. doi: 10.1016/j.ejca.2020.06.018. Epub 2020 Jul 26. PMID: 32721633.

116: Di Nunno V, Franceschi E, Tosoni A, Di Battista M, Gatto L, Lamperini C, Minichillo S, Mura A, Bartolini S, Brandes AA. Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. Expert Rev Anticancer Ther. 2020 Sep;20(9):785-795. doi: 10.1080/14737140.2020.1807949. Epub 2020 Sep 3. PMID: 32799576.

117: Gatto L, Franceschi E, Nunno VD, Brandes AA. Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19. Immunotherapy. 2020 Oct;12(15):1111-1114. doi: 10.2217/imt-2020-0109. Epub 2020 Jun 29. PMID: 32594820; PMCID: PMC7325496.

118: Simonelli M, Franceschi E, Lombardi G. Neuro-Oncology During the COVID-19 Outbreak: A Hopeful Perspective at the End of the Italian Crisis. Front Med (Lausanne). 2020 Nov 27;7:594610. doi: 10.3389/fmed.2020.594610. PMID: 33330558; PMCID: PMC7729058.

119: Franceschi E, De Biase D, Di Nunno V, Pession A, Tosoni A, Gatto L, Tallini G, Visani M, Lodi R, Bartolini S, Brandes AA. IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. Diagnostics (Basel). 2021 Feb 19;11(2):342. doi: 10.3390/diagnostics11020342. PMID: 33669525; PMCID: PMC7922632.

120: Tosoni A, Gatto L, Franceschi E, Di Nunno V, Lodi R, Mura A, Di Battista M, Bartolini S, Brandes AA. Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. Eur J Cancer. 2021 Mar;145:171-178. doi: 10.1016/j.ejca.2020.12.027. Epub 2021 Jan 22. PMID: 33486440.

121: Franceschi E, Brandes AA. Burnout in medical oncology during the COVID-19 pandemic. Expert Rev Anticancer Ther. 2021 Apr;21(4):351-353. doi: 10.1080/14737140.2021.1866549. Epub 2020 Dec 23. PMID: 33353446.

122: Nunno VD, Nuvola G, Mosca M, Maggio I, Gatto L, Tosoni A, Lodi R, Franceschi E, Brandes AA. Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. Immunotherapy. 2021 Apr;13(5):419-432. doi: 10.2217/imt-2020-0208. Epub 2021 Jan 21. PMID: 33472433.

123: Clement PMJ, Dirven L, Eoli M, Sepulveda-Sanchez JM, Walenkamp AME, Frenel JS, Franceschi E, Weller M, Chinot O, De Vos FYFL, Whenham N, Sanghera P, Looman J, Kundu MG, Peter de Geus J, Nuyens S, Spruyt M, Gorlia T, Coens C, Golfinopoulos V, Reijneveld JC, van den Bent MJ. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. Eur J Cancer. 2021 Apr;147:1-12. doi: 10.1016/j.ejca.2021.01.010. Epub 2021 Feb 15. PMID: 33601293.

124: Franceschi E, De Biase D, Di Nunno V, Pession A, Tosoni A, Gatto L, Tallini G, Visani M, Lodi R, Bartolini S, Brandes AA. The clinical and prognostic role of ALK in glioblastoma. Pathol Res Pract. 2021 May;221:153447. doi: 10.1016/j.prp.2021.153447. Epub 2021 Apr 15. PMID: 33887544.

125: Franceschi E, Biase D, Di Nunno V, Pession A, Tosoni A, Gatto L, Lodi R, Tallini G, Visani M, Bartolini S, Brandes AA. IDH1^105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas. Pathol Res Pract. 2021 May;221:153445. doi: 10.1016/j.prp.2021.153445. Epub 2021 Apr 19. PMID: 33887545.

126: Franceschi E, Minichillo S, Tosoni A, Mascarin M, Mura A, Di Battista M, Di Nunno V, Gatto L, Lodi R, Bartolini S, Brandes AA. Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. Tumori. 2021 May 18:3008916211017213. doi: 10.1177/03008916211017213. Epub ahead of print. PMID: 34002658.

127: Maggio I, Franceschi E, Tosoni A, Nunno VD, Gatto L, Lodi R, Brandes AA. Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS Oncol. 2021 Jun 1;10(2):CNS72. doi: 10.2217/cns-2021-0003. Epub 2021 May 21. PMID: 34015955; PMCID: PMC8162186.

128: Visani M, Acquaviva G, De Leo A, Sanza V, Merlo L, Maloberti T, Brandes AA, Franceschi E, Di Battista M, Masetti M, Jovine E, Fiorino S, Pession A, Tallini G, de Biase D. Molecular alterations in pancreatic tumors. World J Gastroenterol. 2021 Jun 7;27(21):2710-2726. doi: 10.3748/wjg.v27.i21.2710. PMID: 34135550; PMCID: PMC8173386.

129: Gatto L, Franceschi E, Tosoni A, Di Nunno V, Maggio I, Lodi R, Brandes AA. IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. Mol Diagn Ther. 2021 Jul;25(4):457-473. doi: 10.1007/s40291-021-00537-3. Epub 2021 Jun 7. PMID: 34095989.

130: Hau P, Frappaz D, Hovey E, McCabe MG, Pajtler KW, Wiestler B, Seidel C, Combs SE, Dirven L, Klein M, Anazodo A, Hattingen E, Hofer S, Pfister SM, Zimmer C, Kortmann RD, Sunyach MP, Tanguy R, Effeney R, von Deimling A, Sahm F, Rutkowski S, Berghoff AS, Franceschi E, Pineda E, Beier D, Peeters E, Gorlia T, Vanlancker M, Bromberg JEC, Gautier J, Ziegler DS, Preusser M, Wick W, Weller M. Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23. Cancers (Basel). 2021 Jul 9;13(14):3451. doi: 10.3390/cancers13143451. PMID: 34298664; PMCID: PMC8303185.

131: Di Nunno V, Franceschi E, Tosoni A, Gatto L, Lodi R, Bartolini S, Brandes AA. Glioblastoma: Emerging Treatments and Novel Trial Designs. Cancers (Basel). 2021 Jul 26;13(15):3750. doi: 10.3390/cancers13153750. PMID: 34359651; PMCID: PMC8345198.

132: Gatto L, Nunno VD, Franceschi E, Brandes AA. Chimeric antigen receptor acrophage for glioblastoma immunotherapy: the way forward. Immunotherapy. 2021 Aug;13(11):879-883. doi: 10.2217/imt-2021-0054. Epub 2021 Jun 3. PMID: 34078139.

133: Franceschi E, Seidel C, Sahm F, Pajtler KW, Hau P. How we treat medulloblastoma in adults. ESMO Open. 2021 Aug;6(4):100173. doi: 10.1016/j.esmoop.2021.100173. Epub 2021 Jun 9. Erratum in: ESMO Open. 2021 Nov 11;6(6):100327. PMID: 34118771; PMCID: PMC8207184.

134: Gatto L, Franceschi E, Tosoni A, Di Nunno V, Maggio I, Tonon C, Lodi R, Agati R, Bartolini S, Brandes AA. Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. Clin Case Rep. 2021 Aug 21;9(8):e04604. doi: 10.1002/ccr3.4604. PMID: 34457284; PMCID: PMC8380081.

135: de Biase D, Acquaviva G, Visani M, Marucci G, De Leo A, Maloberti T, Sanza V, Di Oto E, Franceschi E, Mura A, Ragazzi M, Serra S, Froio E, Bisagni A, Brandes AA, Pession A, Tallini G. Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH. J Mol Diagn. 2021 Sep;23(9):1185-1194. doi: 10.1016/j.jmoldx.2021.06.004. Epub 2021 Jun 26. PMID: 34186176.

136: Di Nunno V, Franceschi E, Tosoni A, Mura A, Minichillo S, Di Battista M, Gatto L, Maggio I, Lodi R, Bartolini S, Brandes AA. Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer? Clin Drug Investig. 2021 Sep;41(9):757-773. doi: 10.1007/s40261-021-01070-1. Epub 2021 Aug17. PMID: 34403132.

137: Gatto L, Franceschi E, Di Nunno V, Tosoni A, Lodi R, Brandes AA. Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. Oncologist. 2021 Oct;26(10):865-878. doi: 10.1002/onco.13858. Epub 2021 Jun 23. PMID: 34105205; PMCID: PMC8488799.

138: Hoogstrate Y, Ghisai SA, de Wit M, de Heer I, Draaisma K, van Riet J, van de Werken HJG, Bours V, Buter J, Vanden Bempt I, Eoli M, Franceschi E, Frenel JS, Gorlia T, Hanse MC, Hoeben A, Kerkhof M, Kros JM, Leenstra S, Lombardi G, Lukacova S, Robe PA, Sepulveda JM, Taal W, Taphoorn M, Vernhout RM, Walenkamp AME, Watts C, Weller M, de Vos FYF, Jenster GW, van den Bent M, French PJ. The EGFRvIII transcriptome in glioblastoma, a meta-omics analysis. Neuro Oncol. 2021 Oct 5:noab231. doi: 10.1093/neuonc/noab231. Epub ahead of print. PMID: 34608482.

139: Maggio I, Franceschi E, Di Nunno V, Gatto L, Tosoni A, Angelini D, Bartolini S, Lodi R, Brandes AA. Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets. Diagnostics (Basel). 2021 Oct 8;11(10):1852. doi: 10.3390/diagnostics11101852. PMID: 34679551; PMCID: PMC8534341.

140: Maggio I, Franceschi E, Gatto L, Tosoni A, Di Nunno V, Tonon C, Brandes AA. Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. Expert Rev Anticancer Ther. 2021 Nov;21(11):1265-1272. doi: 10.1080/14737140.2021.1971518. Epub 2021 Aug 30. PMID: 34433354.

141: Friso F, Rucci P, Rosetti V, Carretta A, Bortolotti C, Ramponi V, Martinoni M, Palandri G, Zoli M, Badaloni F, Franceschi E, Asioli S, Fabbri VP, Rustici A, Foschini MP, Brandes AA, Mazzatenta D, Sturiale C, Conti A. Is There a Role for Surgical Resection of Multifocal Glioblastoma? A Retrospective Analysis of 100 Patients. Neurosurgery. 2021 Nov 18;89(6):1042-1051. doi: 10.1093/neuros/nyab345. PMID: 34662898.

142: Gatto L, Franceschi E, Di Nunno V, Maggio I, Lodi R, Brandes AA. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. Expert Rev Anticancer Ther. 2021 Dec;21(12):1333-1353. doi: 10.1080/14737140.2021.1997599. PMID: 34734551.

143: Nunno VD, Franceschi E, Gatto L, Brandes AA. BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma. Immunotherapy. 2021 Dec 1. doi: 10.2217/imt-2021-0296. Epub ahead of print. PMID: 34850637.

144: Di Nunno V, Franceschi E, Tosoni A, Gatto L, Maggio I, Lodi R, Angelini D, Bartolini S, Brandes AA. Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta- Analysis. Adv Ther. 2021 Dec 1. doi: 10.1007/s12325-021-01977-3. Epub ahead of print. PMID: 34853984.

145: Di Nunno V, Franceschi E, Tosoni A, Gatto L, Maggio I, Lodi R, Bartolini S, Brandes AA. Immune-checkpoint inhibitors in pituitary malignancies. Anticancer Drugs. 2022 Jan 1;33(1):e28-e35. doi: 10.1097/CAD.0000000000001157. PMID: 34348358.

146: Nunno VD, Franceschi E, Gatto L, Brandes AA. BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma. Immunotherapy. 2021 Dec 1. Epub ahead of print.

147: Gatto L, Franceschi E, Tosoni A, Di Nunno V, Bartolini S, Brandes AA. Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment? Cancers (Basel). 2022 Jan 11;14(2):333.

148: Le Rhun E, Devos P, Winklhofer S, Lmalen H, Brandsma D, Kumthekar P, Castellano A, Compter A, Dhermain F, Franceschi E, Forsyth P, Furtner J, Galldiks N, Pérez-Larraya JG, Gempt J, Hattingen E, Hempel JM, Lukacova S, Minniti G, O'Brien B, Postma TJ, Roth P, Rudà R, Schaefer N, Schmidt NO, Snijders TJ, Thust S, van den Bent M, van der Hoorn A, Vogin G, Smits M, Tonn JC, Jaeckle K, Preusser M, Glantz M, Wen PY, Bendzsus M, Weller M. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort. Neuro Oncol. 2022 Feb 14:noac043. Epub ahead of print. PMID: 35157772.

149 : Di Nunno V, Franceschi E, Tosoni A, Gatto L, Bartolini S, Brandes AA. Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance. Front Oncol. 2022 Mar 2;12:852950.

150: Gatto L, Di Nunno V, Franceschi E, Tosoni A, Bartolini S, Brandes AA. Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date? Drugs. 2022 Apr;82(5):491-510.

150: Malvi D, Vasuri F, Maloberti T, Sanza V, De Leo A, Fornelli A, Masetti M, Benini C, Lombardi R, Offi MF, Di Marco M, Ravaioli M, Fiorino S, Franceschi E, Brandes AA, Jovine E, D'Errico A, Tallini G, de Biase D. Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. Diagnostics (Basel). 2022 Apr 23;12(5):1058.

151: Gatto L, Franceschi E, Tosoni A, Nunno VD, Bartolini S, Brandes AA. Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream? Immunotherapy. 2022 Jun 7.

152: Di Nunno V, Fordellone M, Minniti G, Asioli S, Conti A, Mazzatenta D, Balestrini D, Chiodini P, Agati R, Tonon C, Tosoni A, Gatto L, Bartolini S, Lodi R, Franceschi E. Machine learning in neuro-oncology: toward novel development fields. J Neurooncol. 2022 Sep;159(2):333-346.

153: Di Nunno V, Franceschi E, Tosoni A, Gatto L, Bartolini S, Brandes AA. Tumor-Associated Microenvironment of Adult Gliomas: A Review. Front Oncol. 2022 Jul 7;12:891543.

154: Franceschi E, Giannini C, Furtner J, Pajtler KW, Asioli S, Guzman R, Seidel C, Gatto L, Hau P. Adult Medulloblastoma: Updates on Current Management and Future Perspectives. Cancers (Basel). 2022 Jul 29;14(15):3708.

155: Lohmann P, Franceschi E, Vollmuth P, Dhermain F, Weller M, Preusser M, Smits M, Galldiks N. Radiomics in neuro-oncological clinical trials. Lancet Digit Health. 2022 Nov;4(11):e841-e849.

156: Gatto L, Franceschi E, Tosoni A, Di Nunno V, Tonon C, Lodi R, Agati R, Bartolini S, Brandes AA. Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology. Biomedicines. 2022 Dec

9;10(12):3205.

157: Di Nunno V, Franceschi E, Gatto L, Tosoni A, Bartolini S, Brandes AA. How to treat histone 3 altered gliomas: molecular landscape and therapeutic developments. Expert Rev Clin Pharmacol. 2023 Jan;16(1):17-26.

158: Di Nunno V, Gatto L, Tosoni A, Bartolini S, Franceschi E. Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution. Front Oncol. 2023 Jan 4;12:1067252.

159: Gatto L, Franceschi E, Tosoni A, Di Nunno V, Bartolini S, Brandes AA. Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022. Expert Opin Drug Discov. 2023 Mar;18(3):269-286.

160: Di Nunno V, Aprile M, Gatto L, Tosoni A, Ranieri L, Bartolini S, Franceschi E. Tumor Microenvironment in Gliomas: A Treatment Hurdle or an Opportunity to Grab? Cancers (Basel). 2023 Feb 7;15(4):1042.

161: Di Nunno V, Gatto L, Tosoni A, Bartolini S, Franceschi E. Letter concerning "Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival": Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma. Neuro Oncol. 2023 Aug 3;25(8):1546-1547.

162: de Biase D, Franceschi E, Marucci G. Editorial: Advances in brain tumors diagnosis and treatment. Front Med (Lausanne). 2023 May 4;10:1152547.

163: Marvi MV, Neri I, Evangelisti C, Ramazzotti G, Asioli S, Zoli M, Mazzatenta D, Neri N, Morandi L, Tonon C, Lodi R, Franceschi E, McCubrey JA, Suh PG, Manzoli L, Ratti S. Phospholipases in Gliomas: Current Knowledge and Future

Perspectives from Bench to Bedside. Biomolecules. 2023 May 7;13(5):798.

164: Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023 Aug 17;389(7):589-601.

165: Gatto L, Di Nunno V, Tosoni A, Bartolini S, Ranieri L, Franceschi E. DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open. Cancers (Basel). 2023 Jun 20;15(12):3251.

166: Gatto L, Ricciotti I, Tosoni A, Di Nunno V, Bartolini S, Ranieri L, Franceschi E. CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap. Front Oncol. 2023 Jun 16;13:1206983.

167: Tosoni A, Di Nunno V, Gatto L, Corradi G, Bartolini S, Ranieri L, Franceschi E. Olfactory neuroblastoma: diagnosis, management, and current treatment options. Front Oncol. 2023 Oct 16;13:1242453.

168: Cerretti G, Pessina F, Franceschi E, Barresi V, Salvalaggio A, Padovan M, Manara R, Di Nunno V, Bono BC, Librizzi G, Caccese M, Scorsetti M, Maccari M, Minniti G, Navarria P, Lombardi G. Spinal ependymoma in adults: from molecular advances to new treatment perspectives. Front Oncol. 2023 Nov 24;13:1301179.

169: van den Bent M, Saratsis AM, Geurts M, Franceschi E. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions. Neuro Oncol. 2024 May 3;26(Supplement_2):S110-S124.

170: Silvani A, Franceschi E. A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma. Tumori. 2024 Jun;110(3):160-161.

171: Di Nunno V, Aprile M, Bartolini S, Gatto L, Tosoni A, Ranieri L, De Biase D, Asioli S, Franceschi E. The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target?

Cells. 2023 Dec 25;13(1):44.

172: Magnani M, Rustici A, Zoli M, Tuleasca C, Chaurasia B, Franceschi E, Tonon C, Lodi R, Conti A. Connectome-Based Neurosurgery in Primary Intra-Axial Neoplasms: Beyond the Traditional Modular Conception of Brain Architecture for the Preservation of Major Neurological Domains and Higher-Order Cognitive Functions. Life (Basel). 2024 Jan 18;14(1):136

173: Gatto L, Di Nunno V, Tosoni A, Bartolini S, Ranieri L, Franceschi E. Vorasidenib in IDH1/2-mutant low-grade glioma: the grey zone of patient's selection. Front Oncol. 2024 Jan 11;13:1339266.

174: Dipasquale A, Franceschi E, Lombardi G, Simonelli M. Vorasidenib in IDH mutant WHO grade 2 gliomas: time to stop sitting on the fence? Neurooncol Adv. 2024 Jan 9;6(1):vdae003.

175: Blay JY, Casali P, Ray-Coquard I, Seckl MJ, Gietema J, de Herder WW, Caplin M, Klümpen HJ, Glehen O, Wyrwicz L, Peeters R, Licitra L, Girard N, Piperno-Neumann S, Kapiteijn E, Idbaih A, Franceschi E, Trama A, Frezza AM, Hohenberger

P, Hindi N, Martin-Broto J, Schell J, Rogasik M, Lejeune S, Oliver K, de Lorenzo F, Weinman A. Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN. Lancet Reg Health Eur. 2024 Feb 16;39:100861. doi: 10.1016/j.lanepe.2024.100861.

176: Di Nunno V, Lombardi G, Simonelli M, Minniti G, Mastronuzzi A, Di Ruscio V, Corrà M, Padovan M, Maccari M, Caccese M, Simonetti G, Berlendis A, Farinotti M, Pollo B, Antonelli M, Di Muzio A, Dipasquale A, Asioli S, De Biase D, Tosoni A, Silvani A, Franceschi E. The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study. J Neurooncol. 2024 Mar;167(1):145-154.

177: Caccese M, Desideri I, Villani V, Simonelli M, Buglione M, Chiesa S, Franceschi E, Gaviani P, Stasi I, Caserta C, Brugnara S, Lolli I, Bennicelli E, Bini P, Cuccu AS, Scoccianti S, Padovan M, Gori S, Bonetti A, Giordano P, Pellerino A, Gregucci F, Riva N, Cinieri S, Internò V, Santoni M, Pernice G, Dealis C, Stievano L, Paiar F, Magni G, De Salvo GL, Zagonel V, Lombardi G. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma. ESMO Open. 2024 Apr;9(4):102943.

178: Dipasquale A, Franceschi E, Giordano L, Maccari M, Barigazzi C, Di Nunno V, Losurdo A, Persico P, Di Muzio A, Navarria P, Pessina F, Padovan M, Santoro A, Lombardi G, Simonelli M. Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study. ESMO Open. 2024 Jun;9(6):103485.

179: Nunno VD, Aprile M, Gatto L, Tosoni A, Ranieri L, Bartolini S, Franceschi E. Novel insights toward diagnosis and treatment of glioneuronal and neuronal tumors in young adults. CNS Oncol. 2024 Dec 31;13(1):2357532.

180: Di Nunno V, Gatto L, Tosoni A, Aprile M, Galvani L, Zappi A, Foschini MP, Asioli S, Tallini G, De Biase D, Maloberti T, Bartolini S, Giannini C, Franceschi E. TP53 mutations and survival in patients with histologically defined Glioblastoma, IDH-wildtype. Pathol Res Pract. 2024 Aug 8;262:155516.